-$0.19 EPS Expected for AtriCure Inc. (ATRC) This Quarter

Wall Street brokerages forecast that AtriCure Inc. (NASDAQ:ATRC) will announce ($0.19) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for AtriCure’s earnings, with the highest EPS estimate coming in at ($0.17) and the lowest estimate coming in at ($0.20). AtriCure reported earnings of ($0.08) per share during the same quarter last year, which suggests a negative year over year growth rate of 137.5%. The firm is expected to report its next quarterly earnings results on Monday, February 25th.

According to Zacks, analysts expect that AtriCure will report full-year earnings of ($0.87) per share for the current fiscal year, with EPS estimates ranging from ($0.89) to ($0.85). For the next financial year, analysts forecast that the business will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.65) to ($0.39). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow AtriCure.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, November 1st. The medical device company reported ($0.24) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.02). The business had revenue of $49.90 million during the quarter, compared to analysts’ expectations of $49.90 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 10.41%. AtriCure’s revenue for the quarter was up 18.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.22) EPS.

A number of brokerages have weighed in on ATRC. Needham & Company LLC upped their price objective on shares of AtriCure from $36.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, October 4th. Zacks Investment Research cut shares of AtriCure from a “buy” rating to a “hold” rating in a report on Friday, November 30th. Canaccord Genuity increased their price target on shares of AtriCure from $37.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, October 9th. Finally, BidaskClub upgraded shares of AtriCure from a “buy” rating to a “strong-buy” rating in a report on Tuesday, November 27th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $35.20.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Federated Investors Inc. PA bought a new position in AtriCure in the third quarter worth approximately $34,000. Wells Fargo & Company MN raised its position in AtriCure by 3.7% in the third quarter. Wells Fargo & Company MN now owns 62,164 shares of the medical device company’s stock worth $2,177,000 after acquiring an additional 2,213 shares during the period. Teachers Advisors LLC raised its position in AtriCure by 2.8% in the third quarter. Teachers Advisors LLC now owns 84,847 shares of the medical device company’s stock worth $2,972,000 after acquiring an additional 2,333 shares during the period. TIAA CREF Investment Management LLC raised its position in AtriCure by 2.0% in the third quarter. TIAA CREF Investment Management LLC now owns 135,792 shares of the medical device company’s stock worth $4,757,000 after acquiring an additional 2,699 shares during the period. Finally, Rhumbline Advisers raised its position in AtriCure by 9.5% in the second quarter. Rhumbline Advisers now owns 32,455 shares of the medical device company’s stock worth $878,000 after acquiring an additional 2,807 shares during the period. Institutional investors and hedge funds own 81.70% of the company’s stock.

ATRC traded down $0.47 during midday trading on Thursday, reaching $29.68. The company’s stock had a trading volume of 6,055 shares, compared to its average volume of 314,617. The stock has a market cap of $1.20 billion, a PE ratio of -35.78 and a beta of 0.22. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.96 and a current ratio of 2.62. AtriCure has a 1 year low of $14.88 and a 1 year high of $36.49.

About AtriCure

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Recommended Story: How to invest in blue-chip stocks

Get a free copy of the Zacks research report on AtriCure (ATRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit